# US 2015/0104468 A1 · Site-specific labeling methods and molecules produced thereby

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104468 A1
- Document ID: US20150104468A1
- Status: Published application
- Kind: A1
- Application number: 14/402,808
- Filed: 2013-05-31
- Published: 2015-04-16
- Earliest claimed: 2012-06-04
- Assignees: Irm LLC
- Inventors: Bernhard Hubert Geierstanger; Jan Grunewald; Badry Bursulaya
- Web page: https://patentgrep.com/patent/US20150104468A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61K 47/6815: {Enzymes}
- A61K 47/6817: {Toxins}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/30: from tumour cells
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2318/10: Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
- C07K 2319/90: containing a motif for post-translational modification
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.

## Claims

### Claim 1

A modified antibody or fragment thereof, which comprises at least one peptide tag that is a substrate of 4′-phosphopantetheinyl transferase, and is located within the structural loop of said antibody or fragment thereof.

### Claim 2 (depends on 1)

The modified antibody or fragment thereof of claim 1, wherein said 4′-phosphopantetheinyl transferase is Sfp, AcpS, T. maritima PPTase, human PPTase or a mutant or homolog form thereof that retains the 4′-phosphopantetheinyl transferase activity.

### Claim 3 (depends on 1, 2)

The modified antibody or fragment thereof of claim 1 or claim 2, wherein the peptide tag is selected from the group consisting of:
(SEQ ID NO: 1)
GDSLSWLLRLLN,
(SEQ ID NO: 2)
GDSLSWL,
(SEQ ID NO: 3)
GDSLSWLVRCLN,
(SEQ ID NO: 4)
GDSLSWLLRCLN,
(SEQ ID NO: 5)
GDSLSWLVRLLN,
(SEQ ID NO: 6)
GDSLSWLLRSLN,
(SEQ ID NO: 7)
GSQDVLDSLEFIASKLA,
(SEQ ID NO: 8)
VLDSLEFIASKLA,
(SEQ ID NO: 9)
DSLEFIASKLA,
(SEQ ID NO: 10)
GDSLDMLEWSLM,
(SEQ ID NO: 11)
GDSLDMLEWSL,
(SEQ ID NO: 12)
GDSLDMLEWS,
(SEQ ID NO: 13)
GDSLDMLEW,
(SEQ ID NO: 14)
DSLDMLEW,
(SEQ ID NO: 15)
GDSLDM,
(SEQ ID NO: 16)
LDSVRMMALAAR,
(SEQ ID NO: 17)
LDSLDMLEWSLR,
(SEQ ID NO: 18)
DSLEFIASKL,
(SEQ ID NO: 19)
DSLEFIASK,
(SEQ ID NO: 20)
DVLDSLEFI,
(SEQ ID NO: 21)
VLDSLEFIAS,
and
(SEQ ID NO: 1132)
DSLDMLEWSL.

### Claim 4 (depends on 1, 2, 3)

The modified antibody or fragment thereof of any one of claims 1-3, wherein the peptide tag is located within the structural loop of VH, VL, CH1, CH2, CH3, or CL region of the antibody or fragment thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein said the peptide tag is located within the structural loop of the CH1 region of the antibody or fragment thereof.

### Claim 6 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein said peptide tag is inserted between any two amino acids that are listed in Table 1.

### Claim 7 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein the peptide tag is inserted between amino acid residues 2 and 3 of the VH or VL domain, or between amino acid residue 110 and 111 of the light chain, or between 119 and 120, or between 120 and 121, or between 135 and 136, or between 136 and 137, or between 138 and 139, or between 162 and 163, or between 164 and 165, or between 165 and 166, or between 194 and 195, or between 195 and 196 of the CH1 domain, or between 388 and 389, or between 445 and 446, or between 446 and 447 of the CH3 domain of a parental antibody or fragment thereof.

### Claim 8 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein the peptide tag is inserted between amino acid residue 110 and 111 of the light chain, or between 119 and 120, or between 120 and 121, or between 135 and 136, or between 136 and 137, or between 138 and 139, or between 162 and 163, or between 164 and 165, or between 165 and 166, or between 194 and 195, or between 195 and 196 of the CH1 domain, or between 388 and 389 of the CH3 domain of a parental antibody or fragment thereof.

### Claim 9 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein the peptide tag is grafted between amino acid residues 62 to 64 or 62 to 65 of the VH domain, or between amino acid residues 133 and 138 of the CH1 domain, or between 189 and 195 of the CH1 domain, or between 190 and 197 of the CH1 domain.

### Claim 10 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein said antibody comprises SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:32, SEQ ID NO:63, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:139, SEQ ID NO:149, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:160, SEQ ID NO:166, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:248, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:259, SEQ ID NO:265, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:356, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:367, SEQ ID NO:371, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:384, SEQ ID NO:386, SEQ ID NO:387, or SEQ ID NO:388.

### Claim 11 (depends on 1, 2, 3, 4)

The modified antibody or fragment thereof of any one of claims 1-4, wherein said antibody comprises SEQ ID NO:32, SEQ ID NO:63, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:160, SEQ ID NO:166, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:259, SEQ ID NO:265, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:367, SEQ ID NO:371, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:380, SEQ ID NO:381, or SEQ ID NO:384.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The modified antibody or fragment thereof of any one of claims 1-11, wherein the enzyme having 4′-phosphopantetheinyl transferase activity is Sfp and the peptide tag is GDSLSWLLRLLN (SEQ ID NO:1), GDSLSWLVRCLN (SEQ ID NO:3), GDSLSWLLRCLN (SEQ ID NO:4), GDSLSWLVRLLN (SEQ ID NO:5), GDSLSWLLRSLN (SEQ ID NO:6), GSQDVLDSLEFIASKLA (SEQ ID NO:7), VLDSLEFIASKLA (SEQ ID NO:8), DSLEFIASKLA (SEQ ID NO:9), GDSLDMLEWSLM (SEQ ID NO:10), GDSLDMLEWSL (SEQ ID NO:11), GDSLDMLEWS (SEQ ID NO:12), GDSLDMLEW (SEQ ID NO:13), DSLDMLEW (SEQ ID NO:14), LDSLDMLEWSLR (SEQ ID NO:17), DSLEFIASKL (SEQ ID NO:18), DSLEFIASK (SEQ ID NO:19), DSLEFIAS (SEQ ID NO:1116), or DSLDMLEWSL (SEQ ID NO: 1132).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The modified antibody or fragment thereof of any one of claims 1-12, wherein the enzyme having 4′-phosphopantetheinyl transferase activity is Sfp and the peptide tag is GDSLSWLLRLLN (SEQ ID NO:1), GDSLSWL (SEQ ID NO:2), DSLEFIASKLA (SEQ ID NO:9), GDSLDMLEWSLM (SEQ ID NO:10), DSLEFIASKL (SEQ ID NO:18), or DSLEFIASK (SEQ ID NO:19).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The modified antibody or fragment thereof of any one of claims 1-11, wherein the enzyme having 4′-phosphopantetheinyl transferase activity is AcpS and the peptide tag is GDSLDMLEWSLM (SEQ ID NO:10), GDSLDMLEWSL (SEQ ID NO:11), GDSLDMLEWS (SEQ ID NO:12), GDSLDMLEW (SEQ ID NO:13), DSLDMLEW (SEQ ID NO:14), GDSLDM (SEQ ID NO:15), LDSLDMLEWSLR (SEQ ID NO:17), or DSLDMLEWSL (SEQ ID NO: 1132).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The modified antibody or fragment thereof of any one of claims 1-14, wherein the antibody or fragment thereof is an isotype selected from IgG, IgM, IgE and IgA.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The modified antibody or fragment thereof of any one of claims 1-15, wherein the antibody or fragment thereof is a subtype of IgG selected from IgG1, IgG2, IgG3 and IgG4.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The modified antibody or fragment thereof of any one of claims 1-16, wherein the antibody or fragment thereof is a human or humanized antibody or fragment thereof.

### Claim 18 (depends on 17)

The modified antibody or fragment thereof of claim 17, wherein the antibody or fragment thereof is an anti-HER2 antibody or anti-HER2 antibody fragment.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An immunoconjugate comprising the modified antibody or fragment of any one of claims 1-18, and a terminal group.

### Claim 20 (depends on 19)

The immunoconjugate of claim 19, wherein said terminal group is attached to the modified antibody or antibody fragment by a linker having the structure according to Formula (I-b):
wherein:
L1 is a bond, a non-enzymatically cleavable linker, a non-cleavable linker; an enzymatically cleavable linker, a photo stable linker or a photo-cleavable linker;
L2 is a bond, a non-enzymatically cleavable linker, a non-cleavable linker; an enzymatically cleavable linker, a photo stable linker or a photo-cleavable linker;
L3 is a bond, a non-enzymatically cleavable linker, a non-cleavable linker; an enzymatically cleavable linker, a photo stable linker or a photo-cleavable linker;
L4 is a bond, a non-enzymatically cleavable linker, a non-cleavable linker; an enzymatically cleavable linker, a photo stable linker, a photo-cleavable linker or a self-immolative spacer,
the * denotes where the 4′-phosphopantetheinyl moiety is attached to the peptide tag,
and wherein the terminal group is a drug moiety, an affinity probe, a chelator, a spectroscopic probe, a radioactive probe, an imaging reagent, a lipid molecule, a polyethylene glycol, a polymer, a nanoparticle, a quantum dot, a liposome, a PLGA particle, a polysaccharide, an acetyl group, or a surface.

### Claim 21 (depends on 20)

The immunoconjugate of claim 20, wherein
L1 is -A1X2— or —X2—;
L2 is a bond, -A2-, or -A2X2—;
L3 is a bond, -A3-, or -A3X2—;
L4 is a bond, -A4-, -A4X2—,
A1 is —C(═O)NH—, —NHC(═O)—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, or —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—;
A2 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NR4—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —(CH2)nS—, —(C(R4)2)nS—, —S(CH2)n—, —S(C(R4)2)n—, —(CH2)nNH—, —(C(R4)2)nNH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)NH(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)NH(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—,
A3 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —(CH2)nS—, —(C(R4)2)nS—, —S(CH2)n—, —S(C(R4)2)n—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)NH(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)NH(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)—, —(CH2)n(O(CH2)n)mOC(═O)—, —(C(R4)2)n(O(C(R4)2)n)mC(═O)—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—,
A4 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, or —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—;
each X2 is independently selected from a bond,
—S—, —Si(OH)2O—,
—CHR4(CH2)nC(═O)NH—, —CHR4(CH2)nNHC(═O)—, —C(═O)NH— and —NHC(═O)—;
each R4 is independently selected from H, C1-4alkyl, —C(═O)OH and —OH,
each R5 is independently selected from H, C1-4alkyl, phenyl or C1-4alkyl substituted with 1 to 3 —OH groups;
each R6 is independently selected from H, fluoro, benzyloxy substituted with —C(═O)OH, benzyl substituted with —C(═O)OH, C1-4alkoxy substituted with —C(═O)OH and C1-4alkyl substituted with —C(═O)OH;
R7 is independently selected from H, phenyl and pyridine;
R8 is independently selected from
R9 is independently selected from H and C1-6haloalkyl;
each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9, and
each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.

### Claim 22 (depends on 20, 21)

The immunoconjugate of claims 20-21, wherein
L1 is -A1X2— or —X2—;
L2 is a bond, -A2-, or -A2X2—;
L3 is a bond, -A3-, or -A3X2—;
L4 is a bond, -A4-, -A4X2—,
A1 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(CH2)nS—, —(O(CH2)n)m—, —((CH2)nO)m(CH2)n—, —NHC(═O)(CH2)n—, —(CH2)nNHC(═O)—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —(CH2)nNH((CH2)nO)m(CH2)n— or —(O(CH2)n)mNHC(═O)(CH2)n—;
A2 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(CH2)nS—, —(O(CH2)n)m—, —((CH2)nO)m(CH2)n—, —NHC(═O)(CH2)n—, —(CH2)nNHC(═O)—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(O(CH2)n)mNHC(═O)(CH2)n— or
A3 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(CH2)nS—, —(O(CH2)n)m—, —((CH2)nO)m(CH2)n—, —NHC(═O)(CH2)n—, —(CH2)nNHC(═O)—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(O(CH2)n)mNHC(═O)(CH2)n— or
A4 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(CH2)nS—, —(O(CH2)n)m—, —((CH2)nO)m(CH2)n—, —NHC(═O)(CH2)n—, —(CH2)nNHC(═O)—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —(CH2)nNH((CH2)nO)m(CH2)n— or —(O(CH2)n)mNHC(═O)(CH2)n—;
each X2 is independently selected from a bond,
—S—, —Si(OH)2O—,
—CHR4(CH2)nC(═O)NH—, —CHR4(CH2)nNHC(═O)—, —C(═O)NH— and —NHC(═O)—;
each R4 is independently selected from H, C1-4alkyl, —C(═O)OH and —OH,
each R5 is independently selected from H, C1-4alkyl, phenyl or C1-4alkyl substituted with 1 to 3 —OH groups;
each R6 is independently selected from H, fluoro, benzyloxy substituted with —C(═O)OH, benzyl substituted with —C(═O)OH, C1-4alkoxy substituted with —C(═O)OH and C1-4alkyl substituted with —C(═O)OH;
R7 is independently selected from H, phenyl and pyridine;
R8 is independently selected from
R9 is independently selected from H and C1-6haloalkyl;
each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9, and
each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.

### Claim 23 (depends on 20, 21, 22)

The immunoconjugate of claims 20-22, wherein the linker of Formula (I-b) is a linker having the structure according to Formula (I-c):

### Claim 24 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is -A1X2—, where A1 is —C(═O)NH(CH2)nS— and X2 is
L2 is a bond; L3 is a bond, and L4 is -A4- wherein A4 is —(CH2)nNHC(═O)—.

### Claim 25 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is -A1X2—, wherein A1 is —C(═O)NH(CH2)nS— and X2 is
L2 is a bond; L3 is a bond; L4 is -A4-, wherein A4 is —(CH2)nC(═O)—.

### Claim 26 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is -A1X2—, wherein A1 is —C(═O)NH(CH2)nS— and X2 is
L2 is -A2-, wherein A2 is —(CH2)nC(═O;
L3 is -A3-, wherein A3 is
and
L4 is

### Claim 27 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is a -A1X2—, wherein A1 is —C(═O)NH(CH2)nS— and X2 is —(CH2)nC(═O)NH—;
L2 is a bond-; L3 is -A3-, wherein A3 is —(CH2)nC(═O)—, and L4 is a bond.

### Claim 28 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is a -A1X2—, wherein A1 is —C(═O)NH(CH2)nS—, X2 is —CHR4(CH2)nC(═O)NH— and R4 is —C(═O)OH;
L2 is a bond; L3 is -A3-, wherein A3 is —(CH2)nC(═O)— and. L4 is a bond.

### Claim 29 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is -A1X2—, where A1 is —C(═O)NH(CH2)nS— and X2 is —(CH2)C(═O)NH—;
L2 is a bond; L3 is a bond, and L4 is -A4- wherein A4 is —(CH2)nNHC(═O)—.

### Claim 30 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is -A1X2—, wherein A1 is —C(═O)NH(CH2)nS— and X2 is —(CH2)C(═O)NH—;
L2 is a bond; L3 is a bond; L4 is -A4-, wherein A4 is —(CH2)nC(═O)—.

### Claim 31 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is -A1X2—, wherein A1 is —C(═O)NH(CH2)nS— and X2 is —(CH2)C(═O)NH—;
L2 is -A2-, wherein A2 is —(CH2)nC(═O;
L3 is -A3-, wherein A3 is
and
L4 is

### Claim 32 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is a -A1X2—, wherein A1 is —C(═O)NH(CH2)nS— and X2 is —(CH2)C(═O)NH—;
L2 is a bond-; L3 is -A3-, wherein A3 is —(CH2)nC(═O)—, and L4 is a bond.

### Claim 33 (depends on 21, 22)

The immunoconjugate of claims 21-22, wherein
L1 is a -A1X2—, wherein A1 is —C(═O)NH(CH2)nS—, X2 is —CHR4(CH2)nC(═O)NH— and
R4 is —C(═O)OH;
L2 is a bond; L3 is -A3-, wherein A3 is —(CH2)nC(═O)— and. L4 is a bond.

### Claim 34 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The immunoconjugate of any one of claims 19 to 33, wherein the terminal group is a moiety selected from an anti-inflammatory agent, an anticancer agent, an antifungal agent, an antibacterial agent, an anti-parasitic agent, an anti-viral agent and an anesthetic agent.

### Claim 35 (depends on 34)

The immunoconjugate of claim 34, wherein the terminal group is selected from a V-ATPase inhibitor, a HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizers, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor, an inhibitors of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a CDK2 inhibitor, a CDK9 inhibitor, an Eg5 inhibitor, an HDAC inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator, a DNA minor groove binder, a proteasome inhibitor, an RNA polymerase inhibitor, and a DHFR inhibitor.

### Claim 36 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The immunoconjugate of any one of claims 19 to 33, wherein the terminal group is selected from a fluorophore, a chromophore, a quantum dot, a magnetic probe, a radioactive probe, an imaging reagent, or a contrast reagent.

### Claim 37 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The immunoconjugate of any of claims 19-33, wherein the affinity probe is biotin.

### Claim 38 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The immunoconjugate of any one of claims 19-37, wherein said modified antibody or fragment thereof further comprises one or more orthogonal conjugation sites.

### Claim 39 (depends on 38)

The immunoconjugate of claim 38, wherein each orthogonal conjugation site is independently selected from a substrate of Sfp 4′-phosphopantetheinyl transferase, a substrate of AcpS 4′-phosphopantetheinyl transferase, a lysine, a cysteine, a tyrosine, a histidine, a formyl glycine, an unnatural amino acid, pyrrolysine and pyrroline-carboxylysine.

### Claim 40 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A pharmaceutical composition comprising an effective amount of the immunoconjugate of any one of claims 19-39, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The modified antibody or fragment thereof according to any of the claims 1-18, or the immunoconjugate according to any of the claims 19-39 for use as a medicament.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The modified antibody or fragment thereof according to any of the claims 1-18, or the immunoconjugate according to any of the claims 19-39 for use in the treatment of cancer, an inflammatory disease, or an infectious disease.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The modified antibody or fragment thereof according to any of the claims 1-18, or the immunoconjugate according to any of the claims 19-39 for use in the treatment of cancer.

### Claim 44 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method of treating cancer comprising administering to a mammal in need thereof an effective amount of an immunoconjugate according to any one of claims 19-39, or the pharmaceutical composition of claim 40.

### Claim 45 (depends on 44)

The method of claim 44, wherein said mammal is human.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A nucleic acid encoding the modified antibody or fragment thereof of any one of claims 1-18.

### Claim 47 (depends on 46)

A host cell comprising the nucleic acid of claim 46.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The modified antibody of any of claims 1-18 or an antibody fragment thereof that is further conjugated to an anti-cancer agent.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method of producing the immunoconjugate of claims 19-39 comprising incubating under suitable conditions the modified antibody or antibody fragment of any one of claims 1-18, a 4′-phosphopantetheinyl transferase, and a terminal group linked to CoA or a terminal group linked to a CoA analogue, thereby promoting formation of the immunoconjugate which comprises the antibody or antibody fragment and the terminal group linked together by a linker comprising a 4′-phosphopantetheine or a 4′-phosphopantetheine analogue.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method of producing the immunoconjugate of claims 19-39 comprising
i) incubating under suitable conditions an antibody or antibody fragment of any one of claims 1-18 with a 4′-phosphopantetheinyl transferase and a CoA or CoA analogue, thereby attaching a 4′-phosphopantetheine or a 4′-phosphopantetheine analogue to the antibody or antibody fragment, wherein the 4′-phosphopantetheine and the 4′-phosphopantetheine analogue comprises a functional group,
and
ii) reacting the 4′-phosphopantetheine or the 4′-phosphopantetheine analogue with a reactive group optionally linked to a terminal group, thereby forming the immunoconjugate comprising the antibody or antibody fragment and the terminal group linked together by a linker comprising a 4′-phosphopantetheine or a 4′-phosphopantetheine analogue.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method of producing the immunoconjugate of claims 19-39 comprising
i) incubating an under suitable conditions antibody or antibody fragment of any one of claims 1-18 with a 4′-phosphopantetheinyl transferase and a CoA or CoA analogue, thereby attaching a 4′-phosphopantetheine or a 4′-phosphopantetheine analogue to the antibody or antibody fragment, wherein the 4′-phosphopantetheine and the 4′-phosphopantetheine analogue comprises a protected functional group;
ii) deprotecting the protected functional group of the 4′-phosphopantetheine or the 4′-phosphopantetheine analogue,
and
iii) reacting the deprotected functional group of the 4′-phosphopantetheine or the 4′-phosphopantetheine analogue with a reactive group optionally linked to a terminal group, thereby forming the immunoconjugate comprising the antibody or antibody fragment and the terminal group linked together by a linker comprising a 4′-phosphopantetheine or a 4′-phosphopantetheine analogue.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49-51, wherein said the suitable condition comprise a temperature between 4° C. to 37° C. and pH 6.5 to pH 9.0.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An immunoconjugate comprising the modified antibody or antibody fragment of any of claims 1-18, wherein a serine residue of the peptide tag in said modified antibody or antibody fragment is conjugated to a 4′-phosphopantetheine group having the structure of Formula (D-a), Formula (E-a), Formula (F-a) or Formula (G-a):
wherein:
L1 is -A1X2— or —X2—;
L2 is a bond, -A2-, or -A2X2—;
L3 is a bond, -A3-, or -A3X2—;
L4 is a bond, -A4-, -A4X2—,
A1 is —C(═O)NH—, —NHC(═O)—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, or —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—;
A2 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NR4—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —(CH2)nS—, —(C(R4)2)nS—, —S(CH2)n—, —S(C(R4)2)n—, —(CH2)nNH—, —(C(R4)2)nNH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)NH(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)NH(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, —
(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—,
A3 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —(CH2)nS—, —(C(R4)2)nS—, —S(CH2)n—, —S(C(R4)2)n—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)NH(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)NH(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)—, —(CH2)n(O(CH2)n)mOC(═O)—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—,
A4 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, or —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—;
each X2 is independently selected from a bond,
—S—, —Si(OH)2O—,
—CHR4(CH2)nC(═O)NH—, —CHR4(CH2)nNHC(═O)—, —C(═O)NH— and —NHC(═O)—;
each R4 is independently selected from H, C1-4alkyl, —C(═O)OH and —OH,
each R5 is independently selected from H, C1-4alkyl, phenyl or C1-4alkyl substituted with 1 to 3 —OH groups;
each R6 is independently selected from H, fluoro, benzyloxy substituted with —C(═O)OH, benzyl substituted with —C(═O)OH, C1-4alkoxy substituted with —C(═O)OH and C1-4alkyl substituted with —C(═O)OH;
R7 is independently selected from H, phenyl and pyridine;
R8 is independently selected from
R9 is independently selected from H and C1-6haloalkyl;
each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9,
each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9, and
R1 is a thiol, a maleimide, a haloacetamide, an alkyne, a triaryl phosphine, a cyclooctene, an oxanobornadiene, an azide, a diaryl tetrazine, a norbornene, a monoaryl tetrazine, a hydroxylamine, a hydrazine, NH2—NH—C(═O)—, an aldehyde or a ketone.

### Claim 54 (depends on 53)

The immunoconjugate of claim 53 wherein the 4′-phosphopantetheine group is

### Claim 55 (depends on 53)

The immunoconjugate of claim 53 wherein the conjugated serine has a structure selected from:

### Claim 56 (depends on 55)

The immunoconjugate of claim 55 wherein the conjugated serine is

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An immunoconjugate comprising the modified antibody or antibody fragment of any of claims 1-18, wherein a serine residue of the peptide tag in said modified antibody or antibody fragment is conjugated to a modified 4′-phosphopantetheine group and has a structure selected from:
wherein
L1 is -A1X2— or —X2—;
L2 is a bond, -A2-, or -A2X2—;
L3 is a bond, -A3-, or -A3X2—;
L4 is a bond, -A4-, -A4X2—,
A1 is —C(═O)NH—, —NHC(═O)—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, or —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—;
A2 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NR4—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —(CH2)nS—, —(C(R4)2)nS—, —S(CH2)n—, —S(C(R4)2)n—, —(CH2)nNH—, —(C(R4)2)nNH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)NH(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)NH(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—,
A3 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —(CH2)nS—, —(C(R4)2)nS—, —S(CH2)n—, —S(C(R4)2)n—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)NH(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)NH(C(R4)2)n—, —(CH2)n(O(CH2)n)mOC(═O)—, —(C(R4)2)n(O(C(R4)2)n)mOC(═O)—, —(CH2)n(O(CH2)n)mOC(═O)—, —(C(R4)2)n(O(C(R4)2)n)mC(═O)—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—,
A4 is —C(═O)NH—, —C(═O)NH(CH2)n—, —C(═O)NH(C(R4)2)n—, —(O(CH2)n)m—, —(O(C(R4)2)n)m—, —((CH2)nO)m—, —(((C(R4)2)nO)m—, —((CH2)nO)m(CH2)n—, —(((C(R4)2)nO)mC(R4)2)n—, —(CH2)nC(═O)NH—, —(C(R4)2)nC(═O)NH—, —(CH2)nNHC(═O)—, —(C(R4)2)nNHC(═O)—, —NHC(═O)(CH2)n—, —NHC(═O)(C(R4)2)n—, —C(═O)NH(CH2)nS—, —C(═O)NH(C(R4)2)nS—, —S(CH2)nC(═O)NH—, —S(C(R4)2)nC(═O)NH—, —C(═O)NH(CH2)nNHC(═O)(CH2)n—, —C(═O)NH(C(R4)2)nNHC(═O)(C(R4)2)n—, —C(═O)(CH2)n—, —C(═O)(C(R4)2)n—, —(CH2)nC(═O)—, —(C(R4)2)nC(═O)—, —(CH2)n(O(CH2)n)mNHC(═O)(CH2)n—, —(C(R4)2)n(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—, —(CH2)nNHC(═O)(CH2)n—, —(C(R4)2)nNHC(═O)(C(R4)2)n—, —(CH2)nNH((CH2)nO)m(CH2)n—, —(C(R4)2)nNH((C(R4)2)nO)m(C(R4)2)n—, —(O(CH2)n)mNHC(═O)(CH2)n—, or —(O(C(R4)2)n)mNHC(═O)(C(R4)2)n—;
each X2 is independently selected from a bond,
—S—, —Si(OH)2O—,
—CHR4(CH2)nC(═O)NH—, —CHR4(CH2)nNHC(═O)—, —C(═O)NH— and —NHC(═O)—;
each R4 is independently selected from H, C1-4alkyl, —C(═O)OH and —OH,
each R5 is independently selected from H, C1-4alkyl, phenyl or C1-4alkyl substituted with 1 to 3 —OH groups;
each R6 is independently selected from H, fluoro, benzyloxy substituted with —C(═O)OH, benzyl substituted with —C(═O)OH, C1-4alkoxy substituted with —C(═O)OH and C1-4alkyl substituted with —C(═O)OH;
R7 is independently selected from H, phenyl and pyridine;
R8 is independently selected from
R9 is independently selected from H and C1-6haloalkyl;
each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9,
each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9, and
TG is a drug moiety, an affinity probe, a chelator, a spectroscopic probe, a radioactive probe, an imaging reagent, a lipid molecule, a polyethylene glycol, a polymer, a nanoparticle, a quantum dot, a liposome, a PLGA particle, a polysaccharide, an acetyl group, or a surface.

### Claim 58 (depends on 57)

The immunoconjugate of claim 57 wherein the conjugated serine is

### Claim 59 (depends on 58)

The immunoconjugate of claim 58 wherein X2 is
or —(CH2)C(═O)NH—.
